Charles Brenner, PhD, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa Carver College of Medicine, was appointed the Chief Scientific Advisor by ChromaDex
Dr Brenner is a leading expert on nicotinamide riboside (NR), having published 36 research papers and has 6 issued patents on NR and nicotinamide adenine dinucleotide (NAD)-related technologies.
“Dr. Brenner has the most experience designing and conducting studies that measure the unique impacts of NR on NAD-dependent processes in the human body. His knowledge will be instrumental in ensuring we make the best investments in the highest quality research and clinical testing,” said ChromaDex Founder and CEO, Frank Jaksch.
Dr Brenner stated: “There is no question that ChromaDex’s ability to develop and commercialize NR has greatly accelerated the pace of preclinical and clinical testing of this important nutrient. I am grateful for the partnership with ChromaDex and look forward to continued testing of the metabolism-boosting properties of NR, as well as future technologies.”